WO2005092393A1 - Wt1遺伝子の発現を抑制するマイクロrnaおよびその利用 - Google Patents
Wt1遺伝子の発現を抑制するマイクロrnaおよびその利用 Download PDFInfo
- Publication number
- WO2005092393A1 WO2005092393A1 PCT/JP2005/005790 JP2005005790W WO2005092393A1 WO 2005092393 A1 WO2005092393 A1 WO 2005092393A1 JP 2005005790 W JP2005005790 W JP 2005005790W WO 2005092393 A1 WO2005092393 A1 WO 2005092393A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- expression
- rna
- cells
- cancer
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract description 37
- 230000002401 inhibitory effect Effects 0.000 title abstract description 7
- 108091070501 miRNA Proteins 0.000 title abstract description 6
- 101150084041 WT1 gene Proteins 0.000 claims abstract description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 15
- 230000010261 cell growth Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003966 growth inhibitor Substances 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 239000000411 inducer Substances 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 abstract description 29
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 201000011510 cancer Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 108020004705 Codon Proteins 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 53
- 108700011259 MicroRNAs Proteins 0.000 description 48
- 102000040856 WT1 Human genes 0.000 description 27
- 108700020467 WT1 Proteins 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108700025700 Wilms Tumor Genes Proteins 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 6
- 102000008935 SMN Complex Proteins Human genes 0.000 description 5
- 108010049037 SMN Complex Proteins Proteins 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 108091024449 let-7e stem-loop Proteins 0.000 description 4
- 108091044227 let-7e-1 stem-loop Proteins 0.000 description 4
- 108091071181 let-7e-2 stem-loop Proteins 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 102000008167 DEAD Box Protein 20 Human genes 0.000 description 2
- 108010060424 DEAD Box Protein 20 Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- -1 fluidity promoters Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 108091023663 let-7 stem-loop Proteins 0.000 description 2
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 2
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000013549 childhood kidney neoplasm Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 108091053735 lin-4 stem-loop Proteins 0.000 description 1
- 108091032363 lin-4-1 stem-loop Proteins 0.000 description 1
- 108091028008 lin-4-2 stem-loop Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Definitions
- the present invention relates to a microRNA that suppresses the expression of the WT1 gene and use thereof.
- the present invention relates to suppression of cell proliferation using the microRNA.
- WT1 gene is a gene encoding a zinc finger type transcription factor.
- WT1 has 17 amino acids (17AA) inserted in the 5 'side of the two alternative splicing sites in the WT1 gene and 3 amino acid residues between zinc fingers 3-4
- isoforms distinguished by.
- the Wilms tumor gene (WT1 gene) was isolated as a causative gene of childhood renal tumor (Non-patent Documents 1 and 2). This gene has been considered a tumor suppressor gene because it has been found to be defective or mutated in Wilms tumor.
- Non-patent Documents 3 and 4 Leukemia due to WT1 antisense DNA Cell proliferation is specifically suppressed (Non-patent Document 5), mouse normal myeloid progenitor cells and myeloid progenitor cell line 32D C13 suppresses neutrophil differentiation by forced expression of WT1 gene As a result, it has become clear that it has proliferated (Non-Patent Document 6). These findings indicate that the WT1 gene is involved in leukemogenesis of hematopoietic cells. The present inventors have also reported that the wild type WT1 gene is highly expressed in various solid cancers (Non-patent Document 7-14).
- Non-patent document 1 Call KM, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509, 1990
- Non-Special Terms 2 Gessler M, et al: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343 '. 774, 1990
- Non-Special Terms 3 Inoue K, et al: WTl as a Blood 84: 3071, 1994
- Non-specialized literature 4 Inoue K, et al: Aberrant overexpression of the Wilms tumor gene (WTl) in human leukemia. new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 89: 1405, 1997
- Non-patent document 6 Inoue K, et al: Wilms' tumor gene (WTl) competes with differentiation — inducing signal in hematopoietic progenitor cells. Blood 91: 2969, 1998
- Non-patent document 7 Oji, Y., Ogawa, H. , Tamaki, H., Oka, Y., Tsuboi, A., Kim, EH, Soma, ⁇ , Tatekawa, ⁇ , Kawakami, M., Asada, M., Kishimoto, ⁇ , and Sugiyama, H. Expression of the Wilms' tumor gene WTl in solid tumors and its involvement in tumor cell growth. Japanese Journal of Cancer Research, 90: 194-204, 1999.
- Non-Patent Document 8 Oji, ⁇ ⁇ , Miyoshi, S., Maeda, H., Hayashi, S., Tamaki, H., Nakatsuka, S., Yao, M., Takahashi, ⁇ ⁇ , Nakano, ⁇ , Hirabayashi, ⁇ ⁇ , Shintani, ⁇ ⁇ , Oka, ⁇ ⁇ , Tsuboi, A., Hosen, ⁇ ⁇ , Asada, M., Fujioka, ⁇ ⁇ , Murakami, M., Kanato, ⁇ ⁇ ,
- Non-Patent Document 9 Ueda, ⁇ ⁇ , Oji, ⁇ ⁇ , Naka, ⁇ ⁇ , Nakano, ⁇ ⁇ , Takahashi, ⁇ ⁇ , Koga, S., Asada, M., Ikeba, A., Nakatsuka, S., Abeno, S., Hosen, ⁇ ⁇ , Tomita, ⁇ ⁇ , Aozasa, ⁇ ⁇ , Tamai, ⁇ ⁇ , Myoui, A., Yoshikawa, ⁇ ⁇ , and Sugiyama, H .: Overexpression of the Wilms' tumor gene WTl in human bone and soft-tissue sarcomas. Cancer Science, 94: 271-276, 2003.
- Non-Patent Document 10 Oji, Y., Inohara, H., Nakazawa, M., Nakano, Y., Akahani, S.,
- Non-patent literature ll ⁇ ji, ⁇ ⁇ , Miyoshi, ⁇ ⁇ , Koga, S "Nakano, Y" Ando, A "Nakatuska, S. Ikeba, A., Takahashi,., Sakaguchi, ⁇ ⁇ , Yokota, A. , Hosen, ⁇ ⁇ , Ikegame, ⁇ ⁇ , Kawakami, M., Tsuboi, A., Oka, ⁇ ⁇ , Ogawa, ⁇ ⁇ , Aozasa, ⁇ ⁇ , Noguchi, S., and Sugiyama, H. Overexpression of the Wilms 'tumor gene WTl in primary thyroid cancer. Cancer Science, 94: 606-611, 2003.
- Non-Patent Document 12 ⁇ ji, Y., Yamamoto, ⁇ ., Nomura, ⁇ ., Nakano, ⁇ ., Ikeba, A., Nakatsuka, S., Abeno, S., Kiyotoh, ⁇ ⁇ , Jomgeow, ⁇ ⁇ , Sekimoto, M., Nezu, R.,
- Non-Patent Document 13 Oji, ⁇ ⁇ , Miyoshi, S., Takahashi, ⁇ ⁇ , Koga, S., Nakano, ⁇ ⁇ , Shintani, ⁇ ⁇ , Hirabayashi, ⁇ ⁇ , Matsumura, A., Iuchi, uchi ⁇ , Ito, ⁇ ⁇ , Kishimoto, ⁇ ⁇ , Tsuboi, A., Ikegame, ke ⁇ , Hosen, ⁇ ⁇ , Oka, ⁇ ⁇ , Ogawa, ⁇ ⁇ , Maeda, ⁇ ⁇ , Hayashi, S., Kawase, I., and Sugiyama, H. Absence of mutations in the Wilms' tumor gene WTl in de novo non-small cell lung cancers. Neoplasma, 51: 17-20, 2004.
- Non-Patent Document 14 ⁇ ji, ⁇ ⁇ , Miyoshi, ⁇ ⁇ , Kiyotoh, ⁇ ⁇ , Koga, S "Nakano, Y” Ando, A "Hosen, ⁇ ⁇ , Tsuboi, A., Kawakami, M., Ikegame, Ka ⁇ , Oka, ⁇ ⁇ , Ogawa, ⁇ ⁇ , Noguchi, S., and Sugiyama, H. Absence of mutations in the Wilms' tumor gene WTl in primary breast cancer. Jpn J Clin Oncol, 34: 74-7, 2004 .
- Non-Patent Document 15 Experimental Medicine Vol.22 No.4 (March issue) 494-499, 2004
- Non-patent literature 16 ⁇ ji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, Abeno S, i atsumi N, Yokota A, Aoyagi S, Nakazawa T, Ito K, Kanato K, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Aozasa K, Yoshimine T, Sugiyama H: Overexpression of the Wilms' tumor gene WTl in primary astrocytic tumors. Cancer Sci. 95: 822-7, 2004.
- Non-patent literature 17 ⁇ ji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, Fujita S, Kanato K, Ito K, Jomgeow T, Kawakami M , Tsuboi A, Shirakata T, Nishida S, Hosen N, Oka Y, Aozasa K,
- Non-patent literature 18 ⁇ ji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, Yamamoto H, Sakon M, Nezu R, Kawano K, Nishida S , Ikegame K, Kawakami M, Tsuboi A, Oka Y, Yoshikawa K, Aozasa K, Monden M, Sugiyama H .: Overexpression of the Wilms' tumor gene WTl in pancreatic ductal adenocarcinoma. Cancer Sci. 95: 583-7,2004.
- An object of the present invention is to provide a molecule capable of efficiently suppressing the expression of the WT1 gene and to suppress cell proliferation using the molecule.
- the present invention provides a microRNA as a molecule that suppresses the expression of the WT1 gene.
- microRNA that solves the above problems is allowed to act on cancer cells to suppress the expression of WT1.
- Non-patent Document 15 Non-patent Document 15
- the present inventors have found that the microRNA targeting the WT1 gene is It was found that not only the expression is suppressed, but also the cell growth inhibitory effect of the cancer cell line is remarkably exhibited.
- miR115 suppresses the expression of WT1 protein via the virtual target sequence of WTlmRNA, and constructs a vector in which the virtual target sequence is inserted on the 3 'side of GFP protein. This was proved by analyzing the effect of miR115 on the expression of. That is, the present invention relates to cell growth suppression by microRNA targeting WT1, and more specifically, provides the following invention.
- a cell growth inhibitor containing any of the following (a) force and (c) as an active ingredient
- Double-stranded RNA comprising RNA complementary to the transcript of the WTl gene and RNA complementary to the RNA
- FIG. 1 is a view showing complementarity between human miR-115 (SEQ ID NO: 2) and its target region (SEQ ID NO: 1) in WT1 mRNA.
- FIG. 2 is a graph showing changes over time in the growth inhibitory effect of miR-115 on AZ-521 cells.
- FIG. 3 is a graph showing the concentration dependency of the growth inhibitory effect of miR-115 on AZ-521 cells.
- FIG. 4 is a photograph showing suppression of WT1 protein expression by miR-115.
- FIG. 5 is a graph showing that miR-115 has blocked the growth-inhibiting effect on AZ-521 cells by forced expression of WT1.
- FIG. 6 is a diagram showing the structure of a GFP expression vector into which a miR115 virtual target sequence is inserted.
- FIG. 7 is a diagram showing suppression of GFP protein of miRl 15 via miRl 15 virtual target sequence.
- microRNAs are small non-coding RNAs that are seen as RNAs that act on mRNA sequences and cause gene silencing.
- MicroRNA miRNA
- miRNAs The expression process and function of miRNA are considered as follows. From the gene encoding miRNA, precursor RNA of several tens and hundreds of bases is transcribed. The precursor RNA is processed in the nucleus by ribonuclease into stem-loop RNA called pre-miRNA. The pre-miRNA forms a complex with the transport protein and is transported out of the nucleus, where it is sensed by Dicer to become a mature functional miRNA. Mature miRNA is incorporated into the protein complex miRNP. It is thought that this miRNP complex binds to a partially complementary target mRNA and acts to suppress translation. In addition, it has been reported that miRNAs that have complete complementarity with specific mRNA sequences and function as siRNAs exist. While normal miRNA suppresses gene expression by inhibiting translation, Like siRNA, miRNA is thought to suppress gene expression by sequence-specific cleavage of the target mRNA sequence.
- the microRNA of the present invention is a single-stranded RNA complementary to a transcription product of the target WT1 gene. Complementary in the present invention does not necessarily mean completely complementary. In the binding of the microRNA of the present invention and the target WT gene transcript, mismatch (corresponding base is not complementary!), Bulge (base corresponding to one strand is V, etc.) A mating part may be included (see Figure 1).
- the sequence of the transcript of the WT1 gene that is the target of the microRNA of the present invention is not particularly limited as long as it can exhibit a gene expression suppressing effect by binding to the microRNA.
- a preferred example of the target sequence is the sequence of SEQ ID NO: 1.
- the sequence of SEQ ID NO: 1 is the site immediately before the stop codon and is common to four isoforms of the WT1 gene.
- One of the WT1 gene isoforms is shown in SEQ ID NO: 3.
- the target sequence of SEQ ID NO: 1 is present at the 1723 position at position 1739, and the stop codon is also present at the 1738 position at position 1740.
- the start codon is located from position 391 to position 393.
- miR-115 was used as a microRNA targeting the nucleotide sequence set forth in SEQ ID NO: 1.
- the nucleotide sequence of miR-115 is shown in SEQ ID NO: 2.
- miR-115 was identified by Dreyfoss et al. as one of the microRNAs that form the protein complex miRNP (ribonucleaoprotein) together with the constituent proteins eIF2C, Gemin3, and Gemin4.
- Gemin3 and Gemin4 are known to form an SMN complex with Gemin2 and Gemin5 together with a protein that causes spinal muscular atrophy, Survival of Motor Neuron (SMN).
- the number of miR-115 in NCBI GenBank is AF480513.
- the length of the microRNA of the present invention is not limited as long as it has an effect of suppressing the expression of the WT1 gene, but it is preferably 25 bases or less. More preferred is 14-18 bases, and most preferred is 16 bases.
- a target sequence can be selected and prepared from the miRNA of the present invention based on the base sequence of the sequence present in the 3'-UTR region.
- the miRNA of the present invention has a target sequence based on the nucleotide sequence of the WT1 gene transcript. It can be selected and appropriately prepared by a chemical synthesis method or the like.
- the miRNA of the present invention can be directly administered to a living body.
- miRNA can be expressed in vivo by administering DNA encoding miRNA in vivo.
- a viral vector such as a retrovirus, an adenovirus, or Sendai virus
- a non-viral vector such as a ribosome
- administration methods include in vivo methods and ex vivo methods.
- the miRNA of the present invention, the DNA encoding the miRNA, and the vector into which the DNA has been inserted should be used as a cell growth inhibitor, a cell differentiation inducer or a cell death inducer after being mixed with an appropriate compounding agent. Can do. If the drug is introduced into cells using a known transfection reagent, etc., effects such as inhibition of cell growth, induction of cell differentiation, or induction of cell death can be achieved by inhibiting translation of the WT1 transcript or cleaving the WT1 transcript. .
- Cells that are expected to have the effect of the drug according to the present invention are cells that express the WT1 gene. The WT1 gene is highly expressed in cancer cells.
- cancer cells that highly express WT1 include human leukemia, colon cancer, lung cancer, breast cancer, squamous cell carcinoma of the head and neck, stomach cancer, thyroid cancer, bone and soft tissue sarcoma, ovarian cancer, Uterine cancer, kidney cancer, knee cancer, or darioblastoma can be exemplified.
- WT1 does not exert force on normal cells. Therefore, the drug according to the present invention is considered to be effective not only for academic research, but also as a drug for cancer treatment of humans and other mammals, particularly as a drug for cancer treatment targeting the above-listed cancers.
- the cancer therapeutic drug of the present invention is considered to be effective as a drug that acts specifically on cancer cells and causes little damage to normal cells.
- a pharmaceutically acceptable compounding agent in the preparation of the medicament of the present invention, can be mixed.
- Pharmaceutically acceptable compounding agents include, for example, surfactants, excipients, coloring agents, flavoring agents, preservatives, stabilizers, buffering agents, suspending agents, isotonic agents, binders, disintegrating agents, lubricants. Agents, fluidity promoters, flavoring agents, and the like, but are not limited to these, and other commonly used carriers can be used as appropriate.
- Examples of the dosage form of the above preparation include tablets, powders, pills, powders, granules, fine granules, soft and hard capsules, film coating agents, pellets, sublingual agents, and pastes as oral preparations. Examples include parenteral preparations such as injections, suppositories, transdermal preparations, ointments, plasters, and liquids for external use. The optimal dosage form can be selected.
- microRNA (miR) 115 was selected as a candidate from the database (NCBI GenBank), which was likely to serve as a microRNA against the 3'UTR sequence immediately before the stop codon of WT1 mRNA.
- RNA was synthesized by Japan Bioservice. This was dissolved in RNAse free water at a concentration of 100 ⁇ , dispensed, and stored frozen at ⁇ 80 ° C. until use.
- the sequence of the synthesized RNA is as follows. mir— 115: 5 '— uga age gga gcu gga a- 3'
- Gastric cancer cell line AZ-521 cells that highly express WT1 gene were cultured in Dulbecco's Modified Medium (DMEM) containing 10% FBS. Treatment of cells with microRNA after preparing the AZ-521 cells trypsinized in 1.2xl0 5 cells / 2ml, to cells using the RNA (final con 2 ⁇ ⁇ ) the RNAi Fect (QIAGEN) after 24 hours were seeded into 6-well plate Introduced. The number of cells was trypsinized and then calculated using a calculation board.
- DMEM Dulbecco's Modified Medium
- AZ-521 cultured and trypsinized in the same manner as in Example 3 above was prepared to 1.2xl0 5 cells / 2 ml, seeded on a 6-well plate, and 24 hours later, in the presence of RNAi Feet (QIAGEN) miR-115 or Treated with Luciferase AS (concentration 2 ⁇ M) for 12 hours.
- RNAi Feet QIAGEN
- Luciferase AS concentration 2 ⁇ M
- WT1 protein in these cells was analyzed by Western Blot.
- the cells were trypsinized, washed twice with PBS, and then lysed in Laemmieli's SDS sample buffef at a ratio of 10 6 cells / 100 1.
- Proteins were separated by SDS-PAGE, transferred to PVDF membrane, and blocked with 1% gelatin / TBST. This was reacted with the primary antibody anti WT1 C-19 Ab (Santa Curz Biotechnology 100: 1 dilution) or anti GAPDH Ab (1000: 1 dilution), and then reacted with the ALP-labeled secondary antibody for each to react with BCIP / WT1 and GAPDH proteins were detected using an NBT kit strength writer tester.
- a vector pcDNAWTlA (+ / +) was prepared by inserting WT1 17AA (+) KTS (+) into an expression vector pcDNA3.1 (Invitrogen) having a CMV promoter.
- WT1 17AA (+) KTS (+) was prepared by inserting WT1 17AA (+) KTS (+) into an expression vector pcDNA3.1 (Invitrogen) having a CMV promoter.
- pcDNA3.1 Invitrogen
- 2 ⁇ g of vector was Lipofection using Fugene6 (Roche).
- AZ-521 cells were seeded, and RNA (final concentration 2 ⁇ ⁇ ) was introduced into the cells 24 hours later using RNAiFect (QIAGEN). 24 hours later, 2 g of pcDNA3.1 / WTA (+ / +) or empty vector was Lipofectioned, and after 72 hours, each cell was collected and counted. The number of cells was trypsinized and then calculated using a counting plate.
- miRl 15 suppresses WT1 protein expression via the WTlmRNA hypothetical target sequence! / ⁇
- the miRl 15 hypothetical target sequence was inserted 3 'to the GFP protein.
- a vector was constructed and the effect of miRl 15 on intracellular expression of GFP protein was analyzed.
- the oligo DNAs that repeat the base sequence (SEQ ID NO: 5) were inserted into the Scal EcoRI site of pEGFP-c3 vector (BD) to construct pEGFP-115TS vector and pEGFP-115mTS vector (FIG. 6).
- Two types of human miRNA miR-115 5'-UGAAGCGGAGCUGGAA-3 'Let7e: 5 UGAGGUAGGAGGUUGUAUAGU-3' were synthesized (Japan Bio Service).
- a cell line expressing EGFP was treated with microRNA.
- MicroRNA treatment was performed by seeding cells in a 6-well plate the day before and introducing miR-115 and Let7e at a concentration of 2 mg the next day using RNAiFect transfection reagent (QIAGEN). Cells were collected 24 hours later, and the expression level of EGFP was analyzed by the Westamplot method.
- a microRNA capable of efficiently suppressing the expression of the WT1 gene and a cell growth inhibitor containing the microRNA as an active ingredient are provided. Since the WT1 gene is known to be highly expressed in cancer cells, the cell growth inhibitor of the present invention is particularly useful as a novel anticancer agent. In addition, it has been known that overexpression of WT1 suppresses cell differentiation or apoptosis. From this, it is considered that suppression of WT1 expression by miR115 of the present invention induces cell differentiation or cell death in cancer cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05727699A EP1738772A4 (en) | 2004-03-29 | 2005-03-28 | MICRO RNA INHIBITING EXPRESSION OF WT1 GENE AND USE THEREOF |
JP2006511568A JP4762133B2 (ja) | 2004-03-29 | 2005-03-28 | Wt1遺伝子の発現を抑制するマイクロrnaおよびその利用 |
US10/594,706 US20080038819A1 (en) | 2004-03-29 | 2005-03-28 | Micro Rna Inhibiting the Expression of Wt1 Gene and Utilization of the Same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-096877 | 2004-03-29 | ||
JP2004096877 | 2004-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092393A1 true WO2005092393A1 (ja) | 2005-10-06 |
Family
ID=35055999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005790 WO2005092393A1 (ja) | 2004-03-29 | 2005-03-28 | Wt1遺伝子の発現を抑制するマイクロrnaおよびその利用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080038819A1 (ja) |
EP (1) | EP1738772A4 (ja) |
JP (1) | JP4762133B2 (ja) |
WO (1) | WO2005092393A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955848B2 (en) | 2006-04-03 | 2011-06-07 | Trustees Of Dartmouth College | MicroRNA biomarkers for human breast and lung cancer |
EP2374884A3 (en) * | 2006-09-04 | 2012-01-11 | Kyowa Hakko Kirin Co., Ltd. | Human miRNAs isolated from mesenchymal stem cells |
US8192938B2 (en) | 2005-02-24 | 2012-06-05 | The Ohio State University | Methods for quantifying microRNA precursors |
US8207325B2 (en) | 2006-04-03 | 2012-06-26 | Univ. of Copenhagen | MicroRNA biomarkers for human breast and lung cancer |
US8299234B2 (en) | 2004-03-29 | 2012-10-30 | Haruo Sugiyama | siRNA hat inhibits WT1 gene expression and uses thereof |
JP5231997B2 (ja) * | 2006-03-29 | 2013-07-10 | 株式会社癌免疫研究所 | WT117AA(−)アイソフォーム特異的siRNAおよびその利用 |
JP2020195393A (ja) * | 2014-07-15 | 2020-12-10 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法用の操作された細胞 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008084319A2 (ja) * | 2006-12-18 | 2008-07-17 | Kyowa Hakko Kirin Co., Ltd. | 新規核酸 |
JPWO2009148137A1 (ja) * | 2008-06-04 | 2011-11-04 | 協和発酵キリン株式会社 | 肥満細胞の脱顆粒を制御する核酸 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038176A1 (fr) * | 1995-06-01 | 1996-12-05 | Kishimoto, Tadamitsu | Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1) |
WO1999003506A1 (fr) * | 1997-07-16 | 1999-01-28 | Haruo Sugiyama | Medicaments contre une tumeur solide, contenant des inhibiteurs de l'expression du gene (wt1) de la tumeur de wilms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3904260B2 (ja) * | 1995-06-01 | 2007-04-11 | 岸本 忠三 | ウイルムス腫瘍遺伝子(wt1)に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤 |
CA2224970C (en) * | 1996-04-16 | 2002-04-02 | Kishimoto, Tadamitsu | Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantation |
US6232073B1 (en) * | 1999-02-05 | 2001-05-15 | Virginia Commonwealth University | Nucleic acid marker for cancer |
WO2003061386A1 (en) * | 2002-01-03 | 2003-07-31 | Board Of Regents, The University Of Texas System | Wt1 antisense oligos for the inhibition of breast cancer |
US20050118625A1 (en) * | 2003-10-02 | 2005-06-02 | Mounts William M. | Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases |
EP1738771A4 (en) * | 2004-03-29 | 2010-04-21 | Haruo Sugiyama | SIRNA FOR INHIBITING THE EXPRESSION OF WT1 GEN AND ITS USE |
-
2005
- 2005-03-28 US US10/594,706 patent/US20080038819A1/en not_active Abandoned
- 2005-03-28 JP JP2006511568A patent/JP4762133B2/ja not_active Expired - Fee Related
- 2005-03-28 WO PCT/JP2005/005790 patent/WO2005092393A1/ja active Application Filing
- 2005-03-28 EP EP05727699A patent/EP1738772A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038176A1 (fr) * | 1995-06-01 | 1996-12-05 | Kishimoto, Tadamitsu | Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1) |
WO1999003506A1 (fr) * | 1997-07-16 | 1999-01-28 | Haruo Sugiyama | Medicaments contre une tumeur solide, contenant des inhibiteurs de l'expression du gene (wt1) de la tumeur de wilms |
Non-Patent Citations (6)
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299234B2 (en) | 2004-03-29 | 2012-10-30 | Haruo Sugiyama | siRNA hat inhibits WT1 gene expression and uses thereof |
US8603997B2 (en) | 2004-03-29 | 2013-12-10 | Haruo Sugiyama | siRNA that inhibits WT1 gene expression and uses thereof |
US8192938B2 (en) | 2005-02-24 | 2012-06-05 | The Ohio State University | Methods for quantifying microRNA precursors |
JP5231997B2 (ja) * | 2006-03-29 | 2013-07-10 | 株式会社癌免疫研究所 | WT117AA(−)アイソフォーム特異的siRNAおよびその利用 |
US7955848B2 (en) | 2006-04-03 | 2011-06-07 | Trustees Of Dartmouth College | MicroRNA biomarkers for human breast and lung cancer |
US8207325B2 (en) | 2006-04-03 | 2012-06-26 | Univ. of Copenhagen | MicroRNA biomarkers for human breast and lung cancer |
US9056135B2 (en) | 2006-04-03 | 2015-06-16 | Trustees Of Dartmouth College | MicroRNA biomarkers for human breast and lung cancer |
EP2374884A3 (en) * | 2006-09-04 | 2012-01-11 | Kyowa Hakko Kirin Co., Ltd. | Human miRNAs isolated from mesenchymal stem cells |
JP2020195393A (ja) * | 2014-07-15 | 2020-12-10 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法用の操作された細胞 |
JP7224318B2 (ja) | 2014-07-15 | 2023-02-17 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法用の操作された細胞 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005092393A1 (ja) | 2008-02-07 |
EP1738772A1 (en) | 2007-01-03 |
EP1738772A4 (en) | 2007-12-26 |
JP4762133B2 (ja) | 2011-08-31 |
US20080038819A1 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4762133B2 (ja) | Wt1遺伝子の発現を抑制するマイクロrnaおよびその利用 | |
WO2007084954A2 (en) | Selective inhibition of ig20 splice variants to treat cancers | |
JPWO2012121178A1 (ja) | 腫瘍血管形成阻害剤 | |
WO2010136846A1 (en) | Differentiation therapy for sarcomas | |
US8603997B2 (en) | siRNA that inhibits WT1 gene expression and uses thereof | |
US8389711B2 (en) | Pharmaceutical composition for treatment of cancer and asthma | |
US20170016001A1 (en) | Asymmetric interfering rna compositions that silence k-ras and methods of uses thereof | |
KR101413581B1 (ko) | miR-186, miR-216b, miR-337-3p 및 miR-760를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물 | |
CN115768891A (zh) | 用于抑制tdp-43和fus聚集的组合物和方法 | |
US20200370050A1 (en) | Cell proliferation inhibitor and cancer treatment or prevention pharmaceutical composition including cell proliferation inhibitor | |
KR102397455B1 (ko) | PD-1의 발현을 억제하는 비대칭 siRNA | |
US20110009468A1 (en) | Mirna, sirna and use thereof in therapy | |
WO2023040828A1 (zh) | 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用 | |
JP2011188849A (ja) | 抗腫瘍効果を有するmiR−7発現プラスミド | |
EP2258393A1 (en) | Abc transporter protein expression inhibitor | |
AU2008313240A1 (en) | RNAi mediated knockdown of NuMA for cancer therapy | |
JP2024019894A (ja) | ガレクチン-4陽性胃がん治療用医薬組成物 | |
US20120035241A1 (en) | Use of inhibitors of plac8 activity for the modulation of adipogenesis | |
CN116617243A (zh) | miR-299-3p在制备防治肿瘤药物中的应用 | |
KR20140086578A (ko) | HIF1α siRNA 및 항산화제를 함유하는 재발암 또는 내성암의 치료 또는 예방용 약제학적 조성물 | |
KR20160114381A (ko) | CysA5W 펩타이드를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물 | |
JP2009225672A (ja) | FGFR2に対するsiRNAによるスキルス胃がん細胞の増殖阻害 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511568 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727699 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727699 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10594706 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10594706 Country of ref document: US |